Genzyme BioSurgery
This article was originally published in The Gray Sheet
Executive Summary
Enrollment is under way for two separate, six-center, 25-patient, placebo-controlled U.S. trials of the HIF-1alpha angiogenesis product for use as an adjunct to CABG surgery, and for peripheral vascular disease, respectively. "The Gray Sheet" (Feb. 19, 2001, p. 18) incorrectly reported the studies were being conducted in Europe. In addition, the firm intends to start clinical trials for its second generation Carticel product in Europe sometime this year. The current version delivers harvested cartilage cells through open-knee surgery and not arthroscopically. Planned improvements will not include elimination of the cell harvesting procedure
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.